Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Regulation of osteoclast differentiation and function by the CaMK-CREB pathway

Article Abstract:

The effects of pharmacological inhibition of CaMKs were investigated by using an in vitro osteoclast culture system to test whether the role of C[a.sub.2.plus]/calmodulin in osteoclastogenesis is mediated through CaMKs. The CaMK-CREB pathway biphasically functions to regulate the transcriptional program of osteoclastic bone resorption by not only enhancing induction of NFATc1 but also facilitating NFATc1-dependent gene regulation once its expression is induced.

Author: Yamaguchi, Akira, Kodama, Tatsuhiko, Takayanagi, Hiroshi, Morishita, Yasuyuki, Aoki, Kazuhiro, Ohya, Keiichi, Nakashima, Tomoki, Sato, Kojiro, Suematsu, Ayako, Takemoto-Kimura, Sayaka, Asahara, Hiroshi, Takai, Toshiyuki, Chatila, Talal A., Bito, Haruhiko
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2006
Japan, Physiological aspects, Cell differentiation, Cyclic adenylic acid, Cyclic adenosine monophosphate, Osteoclasts (Biology)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Selective inhibition of NF-kappa blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo

Article Abstract:

Blocking NF-kappa B is believed to be potential strategy to prevent inflammatory bone resorption. However, extensive pharmacological evaluation is required to understand the effects of long-term use of NBD peptide to treat chronic inflammatory diseases.

Author: Saito, Hiroaki, Aoki, Kazuhiro, Jimi, Eijiro, Acquisto, Fulvio D', May, Michael J., Ghosh, Shankar, Ohya, Keiichi, Okabe, Koji, Fukushima, Hidefumi, Okamoto; Fujio, Takefumi Kojima, Sudo, Testuo, Nakamura, Ichiro
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2004
Care and treatment, Evaluation, Risk factors, Chronic diseases, Osteogenesis imperfecta, Pharmacology, Experimental, Pharmacological research

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


NFAT and Osterix cooperatively regulate bone formation

Article Abstract:

The administration of FK506 is responsible for inducing the reduction of bone mass in spite of a blockade of osteoclast differentiation. Osteoblastic bone formation is cooperatively controlled by nuclear factor of activated T cells (NFAT) and Osterix.

Author: Kodama, Tatsuhiko, Koga, Takako, Takayanagi, Hiroshi, Asagiri, Masataka, Matsui, Yuichi, Crombrugghe, Benoit de, Nakashima Kazuhisa
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2005
United States, Science & research, Research, Usage, Bones, Bone density, Immune response, Immunosuppressive agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Similar abstracts:
  • Abstracts: Prediction of germline mutations and cancer risk in the Lynch syndrome. History and molecular genetics of Lynch syndrome in family G
  • Abstracts: Regulation of lung injury and repair by Toll-like receptors and hyaluronan. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment
  • Abstracts: Raising the status of stroke. Advances in prevention and treatment of stroke and TIA
  • Abstracts: Simulation training in the obstetrics and gynecology clerkship. Medical student evaluation of teaching quality between obstetrics and gynecology residents and faculty as clinical preceptors in ambulatory gynecology
  • Abstracts: Relationship between Medicare's Hospital Compare performance measures and mortality rates. Risk stratification for In-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.